Pharmaceuticals

With the FDA mandating a move from animal testing, BioIVT is positioning itself at the center of the NAMs revolution with key industry events and research.

ImmunoBrain's novel immunotherapy for Alzheimer's avoids key safety issues of other drugs and shows positive biomarker data in a Phase 1b trial.

LGM Pharma is investing $15 million to expand its Texas and Colorado sites, boosting domestic production of specialized drugs and fortifying the U.S. supply chain.

With a new CFO who helped steer a multi-billion dollar acquisition, Bambusa Therapeutics signals major growth plans for its innovative antibody platform.

A new biotech spins out with a novel drug class aiming to provide healthier, more durable weight loss and combat cancer-related wasting syndrome.

Ractigen's RAG-01 advances with NMPA approval, using RNA activation to fight bladder cancer by targeting a previously 'undruggable' gene.

A new drug shows unprecedented activity against all common cold viruses, a major breakthrough for millions suffering from chronic lung diseases.

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

A new $7 million deal will use a digital marketplace to deliver 16 million doses of a life-saving antibiotic to children in Burkina Faso. But can it work?

Belief BioMed's single-dose treatment for hemophilia B, BBM-H901, is now approved in Macao, offering a new horizon for patients beyond frequent injections.

A landmark study reveals GLP-1 drugs like Ozempic dramatically reduce risks of depression and anxiety, hinting at a new era for mental healthcare.

The 'Beauty in Black' star, whose character has prostate cancer, is now a Global Ambassador for ZERO, tackling the disease's deadly toll on Black men.

As AI reshapes work, BetterUp's Uplift 2026 brings together Hollywood stars, sports legends, and CEOs to argue that our humanity is the ultimate advantage.

Amid massive layoffs and AI-driven shifts, the life sciences industry faces a structural crisis. Blue Matter's new practice offers a roadmap to survive.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

With a major Series B financing, Crossbow advances its TCR-mimetic therapies, aiming to unlock a new frontier in the fight against a broad range of cancers.

Biotech firm ProMIS Neurosciences reveals novel vaccine data for ALS and Parkinson's, using a platform that selectively targets only toxic proteins.

Cingulate Inc. faces a critical FDA decision for its novel ADHD drug, but manufacturing queries and a tight cash runway create a high-stakes countdown.

Artelo Biosciences is testing a novel cannabinoid drug for glaucoma, aiming to protect vision in a way current treatments can't—all without diluting shares.

A new partnership will leverage genetically engineered mice to create novel antibody drugs, potentially unlocking treatments for cancer and brain diseases.